Opdivo Fails NSCLC Test
Ono Pharmaceutical's US partner, Bristol Myers Squibb reported that Opdivo didn’t meet its primary goal of lengthening progression-free survival in...
287 Views
No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron
The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations...
255 Views
Brexit; Unintended Consequences
In this brief piece we take a considered stance on the likelihood of Brexit actually proceeding in the wake of June’s referendum and examine some...
326 Views
The Path to No Brexit
In my last piece I discussed why I thought an actual Brexit was unlikely despite the result of the referendum last week. This piece answers some...
412 Views
Why Brexit (Probably) Won't Happen
The last few days have seen a maelstrom of opinions and recrimination after the shock referendum decision to leave the EU.The lack of a concrete...
668 Views